↓ Skip to main content

Cochrane Database of Systematic Reviews

Alemtuzumab for patients with chronic lymphocytic leukaemia

Overview of attention for article published in Cochrane database of systematic reviews, February 2012
Altmetric Badge

Mentioned by

twitter
2 tweeters
facebook
1 Facebook page

Citations

dimensions_citation
49 Dimensions

Readers on

mendeley
152 Mendeley
Title
Alemtuzumab for patients with chronic lymphocytic leukaemia
Published in
Cochrane database of systematic reviews, February 2012
DOI 10.1002/14651858.cd008078.pub2
Pubmed ID
Authors

Nicole Skoetz, Kathrin Bauer, Thomas Elter, Ina Monsef, Verena Roloff, Michael Hallek, Andreas Engert

Abstract

Chronic lymphocytic leukaemia (CLL) accounts for 25% of all leukaemias and is the most common lymphoid malignancy in Western countries. Standard treatment  includes mono- or poly-chemotherapies. Nowadays, monoclonal antibodies are added, especially alemtuzumab and rituximab. However, the impact of these agents remains unclear, as there are hints of an increased risk of severe infections.

Twitter Demographics

The data shown below were collected from the profiles of 2 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 152 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Mexico 1 <1%
United States 1 <1%
France 1 <1%
Unknown 149 98%

Demographic breakdown

Readers by professional status Count As %
Student > Master 23 15%
Other 18 12%
Researcher 17 11%
Student > Bachelor 16 11%
Student > Postgraduate 12 8%
Other 31 20%
Unknown 35 23%
Readers by discipline Count As %
Medicine and Dentistry 60 39%
Agricultural and Biological Sciences 12 8%
Nursing and Health Professions 10 7%
Psychology 7 5%
Biochemistry, Genetics and Molecular Biology 6 4%
Other 18 12%
Unknown 39 26%

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 02 May 2019.
All research outputs
#15,242,272
of 22,663,150 outputs
Outputs from Cochrane database of systematic reviews
#10,763
of 12,296 outputs
Outputs of similar age
#165,490
of 250,716 outputs
Outputs of similar age from Cochrane database of systematic reviews
#166
of 217 outputs
Altmetric has tracked 22,663,150 research outputs across all sources so far. This one is in the 22nd percentile – i.e., 22% of other outputs scored the same or lower than it.
So far Altmetric has tracked 12,296 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 30.3. This one is in the 8th percentile – i.e., 8% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 250,716 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 22nd percentile – i.e., 22% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 217 others from the same source and published within six weeks on either side of this one. This one is in the 15th percentile – i.e., 15% of its contemporaries scored the same or lower than it.